Capsida Biotherapeutics to Showcase Innovative Programs
Capsida Biotherapeutics, a frontrunner in targeted gene therapy, is preparing to present at several key investor and industry conferences. These events will highlight the significant progress made in its wholly owned programs, particularly those aimed at treating **genetic epilepsy** linked to STXBP1 mutations and **Parkinson's disease** associated with GBA mutations. Both programs are expected to enter clinical trials by the first half of 2025, marking a crucial milestone for the company as it strives to tackle urgent medical issues.
Upcoming Conferences and Presentations
The management team at Capsida is eager to showcase its advancements at several prominent conferences scheduled in the near future:
Morgan Stanley Healthcare Conference
This esteemed conference will occur in early September. Capsida is slated to deliver a corporate presentation on Thursday, September 5, 2024, at **4:05 PM ET**. This event offers a valuable opportunity for the company to engage with key stakeholders in the healthcare arena.
Mass General Brigham World Medical Innovation Forum
Later in September, Capsida will take part in a panel discussion that will focus on the future of viral vector manufacturing and the delivery of genetic medicines. This session is part of the **Mass General Brigham World Medical Innovation Forum**, running from September 23-25, 2024, with Capsida’s involvement scheduled for **Monday, September 23rd** at **4:05 PM ET**.
Bank of America Healthcare Trailblazers Conference
On September 25, 2024, Capsida will hold one-on-one investor meetings at the Bank of America Healthcare Trailblazers Conference. This setting will provide a unique platform for in-depth discussions about the company's innovative strategies and future prospects. The event will take place in Boston.
Chardan's Annual Genetic Medicines Conference
Wrapping up the month, Capsida will not only deliver a corporate presentation but also participate in various panels at Chardan's **8th Annual Genetic Medicines Conference** from September 30 to October 1, 2024. A significant panel titled 'Engineering of AAVs: The Promise of Next Gen AAVs' is scheduled for **Monday, September 30**, with discussions commencing at **9:30 AM ET**.
Cell & Gene Meeting on the Mesa
In early October, Capsida will conclude its conference participation at the **Cell & Gene Meeting on the Mesa**, set for October 7-9, 2024. The corporate presentation is scheduled for **October 8**, and attendees can look forward to engaging discussions centered on Capsida’s innovative approaches in gene therapy.
About Capsida Biotherapeutics
Capsida Biotherapeutics is a fully integrated gene therapy company that employs cutting-edge strategies to develop disease-modifying treatments for both rare and more prevalent diseases affecting individuals of all ages. The company's intravenously administered gene therapies utilize proprietary engineered capsids, which enhance the delivery of therapeutic agents while minimizing impact on non-target organs, such as the liver. Currently, Capsida has three wholly owned programs aimed at delivering best-in-class treatments for the aforementioned genetic conditions, all within the framework of IND-enabling studies and poised for clinical entry in the near future.
Additionally, Capsida maintains collaborative partnerships with major players like AbbVie and Lilly, bolstering its capabilities in the central nervous system therapeutics field. Founded in 2019 with visionary investments from Versant Ventures and Westlake Village BioPartners, the company has its roots in groundbreaking research led by Dr. Viviana Gradinaru at Caltech.
Frequently Asked Questions
What is the focus of Capsida Biotherapeutics?
Capsida Biotherapeutics specializes in targeted gene therapy for a variety of diseases, particularly genetic epilepsy and Parkinson's disease.
When are the upcoming conferences where Capsida will present?
Capsida will be presenting at several upcoming conferences, including the Morgan Stanley Healthcare Conference in early September and the Cell & Gene Meeting on the Mesa in October.
What key presentations will Capsida make?
Capsida will showcase its intravenous programs CAP-002 and CAP-003, which target genetic epilepsy and Parkinson’s disease, respectively.
Who are Capsida’s strategic partners?
Capsida has formed validating partnerships with prominent companies, including AbbVie, Lilly, and CRISPR Therapeutics.
When can Capsida's corporate presentation be viewed?
The Capsida corporate presentation will be available on the company's website in the News section.
